FDA announced a proposal concerning semaglutide, tirzepatide, and liraglutide and the 503B bulks list used by outsourcing facilities. 1
The agency action is a proposal, not a final rule or a statement that all compounding circumstances are identical. This update preserves that procedural distinction. 1
What this source can tell us. PeptideScanner is reporting the cited regulator or label record. The summary does not extend that record into broader safety, effectiveness, or approval claims.